A 35-yr-old woman with rheumatoid arthritis, receiving cyclosporin A, presented with diplopia, ptosis, loss of horizontal and vertical eye movements, dysarthria, nasal regurgitation. After differential diagnosis, cyclosporin A neurotoxicity was suspected and the treatment stopped. All side-effects were reversed with the discontinuation of the drug. Central nervous system neurotoxicity with low-...

Introduction: Hypertension has emerged as a serious adverse effect of immunosuppression with cyclosporin, which has become the mainstay of immunosuppression in organ transplantation. Improved survival rates with cyclosporin compared to previous regimens based on corticosteroids and azathioprine were established and have led to an expansion of solid organ transplantation. Cyclosporin has also be...

To determine if exogenous gamma interferon is effective in immunosuppressed mice infected with Trypanosoma cruzi, recombinant murine gamma interferon was administered to cyclosporin-treated mice with either acute or chronic T. cruzi infection. Gamma interferon significantly decreased parasitemia and prevented death in acutely infected mice. Parasitemias and mortality of mice treated with both g...

Cyclosporin A (ciclosporin), a potent and clinically important immunosuppressive drug (Sandimmun), represents the main component of a group of over 25 closely related, cyclic undecapeptides produced by the fungus Tolypocladium inflatum. By feeding experiments using DL-alpha-allylglycine as precursor, specific incorporation in position 2 was attained leading to [Allylgly2]cyclosporin A. Exogenou...

The use of cyclosporin is well established within the ophthalmology community, especially against sight threatening intraocular inflammation. It is well known however, that immunosuppression in general is a risk factor for the development of malignancy and numerous studies point to the risk imposed by cyclosporin. This article analyses and reviews all relevant studies with regard to the develop...

Cyclosporin A (CsA) is an immunosuppressant drug widely used in organ transplant recipients and patients with auto-immune disorders. Long-term treatment with CsA is associated with hyperlipidemia and an increased risk of atherosclerosis. The mechanisms by which cyclosporin A causes hyperlipidemia are unclear. Cell and animal studies have pointed to various mechanisms that may mediate CsA-induce...

Liver functional abnormalities were seen in 13 (19.7%) of 66 recipients of cadaveric renal homografts treated with cyclosporin A and prednisone. However, such presumed hepatotoxicity was a minor problem in the use of cyclosporin A. The complication was less frequent than that of nephrotoxicity, was as easily manageable with reductions in the cyclosporin A dosage, and generally did not cause cli...

In two consecutive prospective randomised trials cyclosporin A has been compared with conventional immunosuppressive therapy (azathioprine and steroids) and with cyclosporin combined with steroids. The present report is a 4 year review and includes 165 patients.Cyclosporin A alone had a significant advantage over conventional therapy at both 1 and 3 years (p = 0.02) for both patient and graft s...